158 related articles for article (PubMed ID: 33680575)
1. DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods.
Rohani N; Ahmadi Moughari F; Eslahchi C
PeerJ; 2021; 9():e10505. PubMed ID: 33680575
[TBL] [Abstract][Full Text] [Related]
2. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.
Hasan M; Ashik AI; Chowdhury MB; Tasnim AT; Nishat ZS; Hossain T; Ahmed S
Inform Med Unlocked; 2021; 24():100569. PubMed ID: 33846694
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Regulator miRNA Pattern Differences Among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 World-Wide Isolates Delineated the Mystery Behind the Epic Pathogenicity and Distinct Clinical Characteristics of Pandemic COVID-19.
Khan MA; Sany MRU; Islam MS; Islam ABMMK
Front Genet; 2020; 11():765. PubMed ID: 32765592
[TBL] [Abstract][Full Text] [Related]
4. CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2.
Gupta AK; Khan MS; Choudhury S; Mukhopadhyay A; Sakshi ; Rastogi A; Thakur A; Kumari P; Kaur M; Shalu ; Saini C; Sapehia V; Barkha ; Patel PK; Bhamare KT; Kumar M
Front Microbiol; 2020; 11():1858. PubMed ID: 32849449
[TBL] [Abstract][Full Text] [Related]
5. Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs.
Pierce JB; Simion V; Icli B; Pérez-Cremades D; Cheng HS; Feinberg MW
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33207533
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach.
Yousefi H; Poursheikhani A; Bahmanpour Z; Vatanmakanian M; Taheri M; Mashouri L; Alahari SK
Biomed Pharmacother; 2020 Oct; 130():110548. PubMed ID: 33475497
[TBL] [Abstract][Full Text] [Related]
7. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.
Glinsky GV
Biomedicines; 2020 May; 8(5):. PubMed ID: 32455629
[TBL] [Abstract][Full Text] [Related]
8. Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection.
Saçar Demirci MD; Adan A
PeerJ; 2020; 8():e9369. PubMed ID: 32547891
[TBL] [Abstract][Full Text] [Related]
9. Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2.
Baldassarre A; Paolini A; Bruno SP; Felli C; Tozzi AE; Masotti A
Epigenomics; 2020 Aug; 12(15):1349-1361. PubMed ID: 32875809
[TBL] [Abstract][Full Text] [Related]
10. Dataset of mutational analysis, miRNAs targeting SARS-CoV-2 genes and host gene expression in SARS-CoV and SARS-CoV-2 infections.
Sardar R; Satish D; Birla S; Gupta D
Data Brief; 2020 Oct; 32():106207. PubMed ID: 32864402
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
12. To accelerate the Zika beat: Candidate design for RNA interference-based therapy.
Giulietti M; Righetti A; Cianfruglia L; Šabanović B; Armeni T; Principato G; Piva F
Virus Res; 2018 Aug; 255():133-140. PubMed ID: 30031046
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 (Novel Coronavirus 2019) - recent trends.
Kannan S; Shaik Syed Ali P; Sheeza A; Hemalatha K
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):2006-2011. PubMed ID: 32141569
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2.
Natarelli L; Parca L; Mazza T; Weber C; Virgili F; Fratantonio D
Noncoding RNA; 2021 Feb; 7(1):. PubMed ID: 33670580
[TBL] [Abstract][Full Text] [Related]
15. Design of Potential RNAi (miRNA and siRNA) Molecules for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Gene Silencing by Computational Method.
Nur SM; Hasan MA; Amin MA; Hossain M; Sharmin T
Interdiscip Sci; 2015 Sep; 7(3):257-65. PubMed ID: 26223545
[TBL] [Abstract][Full Text] [Related]
16. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
17. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets.
Agrawal L; Poullikkas T; Eisenhower S; Monsanto C; Bakku RK; Chen MH; Kalra RS
Antibodies (Basel); 2021 Jan; 10(1):. PubMed ID: 33440681
[TBL] [Abstract][Full Text] [Related]
18. Global cataloguing of variations in untranslated regions of viral genome and prediction of key host RNA binding protein-microRNA interactions modulating genome stability in SARS-CoV-2.
Mukherjee M; Goswami S
PLoS One; 2020; 15(8):e0237559. PubMed ID: 32780783
[TBL] [Abstract][Full Text] [Related]
19. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.
Tsuji M
FEBS Open Bio; 2020 Jun; 10(6):995-1004. PubMed ID: 32374074
[TBL] [Abstract][Full Text] [Related]
20. SMRI: A New Method for siRNA Design for COVID-19 Therapy.
Chen MX; Zhu XD; Zhang H; Liu Z; Liu YN
J Comput Sci Technol; 2022; 37(4):991-1002. PubMed ID: 35992496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
